

Maximizing Novel Therapeutic Strategies for Moderate to Severe Plaque Psoriasis

1181-104

WEDNESDAY, JULY 23, 2014

Registration: 10:00 am, Session: 10:15 – 11:15 am

PRESENTER

Andrew Blauvelt, MD, MBA
Oregon Medical Research Center

**University of California, Irvine
Department of Dermatology**

Weinstein Library
125 Med Surge 1 (Bldg. 810)
One Medical Plaza, Irvine, CA 92697

TARGET AUDIENCE

This activity is intended for primary care physicians, dermatologists, pharmacists, rheumatologists, managed care professionals, and other healthcare professionals who care for patients with moderate to severe plaque psoriasis.

PURPOSE

The goal of this activity is to close clinical knowledge and competence gaps by providing clinicians with the latest advancements and emerging research in the management of moderate to severe plaque psoriasis.

ACTIVITY OVERVIEW

Psoriasis is a chronic inflammatory skin condition that is often associated with systemic manifestations. It affects about 2 percent of U.S. adults, and can significantly impact quality of life. The etiology includes genetic and environmental factors. Diagnosis is based on the typical erythematous, scaly skin lesions, often with additional manifestations in the nails and joints. Plaque psoriasis is the most common form. Atypical forms include guttate, pustular, erythrodermic, and inverse psoriasis. Psoriasis is associated with several comorbidities, including cardiovascular disease, lymphoma, and depression. Topical therapies such as corticosteroids, vitamin D analogs, and tazarotene are useful for treating mild to moderate psoriasis. More severe psoriasis may be treated with phototherapy, or may require systemic therapy. Biologic therapies, including tumor necrosis factor inhibitors, can be effective for severe psoriasis, but have significant adverse effect profiles and require regular monitoring. Management of psoriasis must be individualized and may involve combinations of different medications and phototherapy.

Primary care physicians, dermatologists, rheumatologists, pharmacists, and other healthcare providers involved in the diagnosis and management of patients with moderate to severe plaque psoriasis must be fully apprised of the latest clinical challenges, current treatment options, and emerging data on novel agents and regimens in order to maximize patient outcomes and quality of life. The proposed webinars and series of live grand rounds seek to address these educational needs while bridging existing knowledge and performance gaps to improve the clinical outcomes of patients with moderate to severe plaque psoriasis.

LEARNING OBJECTIVES

At the conclusion of this activity, participants should be able to:

- Explain the immunopathology of moderate to severe plaque psoriasis
- Utilize knowledge of key clinical presentation and patient

characteristics in treatment decision-making for patients with moderate to severe plaque psoriasis

- Implement treatment plans based upon the safety and efficacy of current anti-tumor necrosis factor alpha therapies in the long-term management of patients with moderate to severe plaque psoriasis
- Analyze emerging data on novel small molecule PDE4 and anti-interleukin 17 therapies for moderate to severe plaque psoriasis to integrate these regimens into the treatment algorithm
- Provide accurate and appropriate counsel as part of the psoriasis treatment team

CHAIRPERSON

Alan Menter, MD
Baylor University Medical Center
University of Texas, Southwestern Medical Center
Baylor Psoriasis Research Center
Dallas, TX

ACTIVITY AGENDA

- Introduction (5 mins)
- Understanding the Pathogenesis and Diagnosis of Plaque Psoriasis (10 mins)
- Current Clinical Management of Plaque Psoriasis (15 mins)
- Promising Novel Therapies For the Management of Moderate to Severe Plaque Psoriasis (15 mins)
- Idea Exchange (15 mins)

There is no fee for this educational activity.

Jointly sponsored by:



Postgraduate Institute
for Medicine



This activity is supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding visit <http://www.lillygrantoffice.com>.

Maximizing Novel Therapeutic Strategies for Moderate to Severe Plaque Psoriasis

1181-104

PHYSICIAN CONTINUING MEDICAL EDUCATION

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and AXIS. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.

PHARMACY CONTINUING MEDICAL EDUCATION

Accreditation Statement



Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0809-9999-14-103-L01-P)

TYPE OF ACTIVITY

Application

For Pharmacists: Upon receipt of the completed activity evaluation form, you will receive an email from the Postgraduate Institute for Medicine within 3 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service.

AMERICANS WITH DISABILITIES ACT

In compliance with the Americans with Disabilities Act, we will make every reasonable effort to accommodate your request. For any special requests, please contact AXIS at 954-445-0760 before the meeting dates.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

SAFEGUARDS AGAINST COMMERCIAL BIAS

Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education's content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:

1. Fair balance
 - a. Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
 - b. No single product or service is overrepresented when other equal competing products or services are available for inclusion
2. Scientific objectivity of studies mentioned in the materials or used as the basis for content
3. Appropriateness of patient care recommendations made to learners